Anti-thrombotic therapy Flashcards

1
Q

What is the most important feature of the haemostatic system?

A

Maintain integrity of vascular endothelium

Maintain blood fluidity (balance between haemorrhage and thrombosis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is a thrombus?

A

Solid clot made by platelets, fibrin and trapped blood cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is primary thrombosis?

A

Partial or total obstruction of blood vessel by thrombi

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is an embolism?

A

Migration of a clot or part of it to another site

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is a thromboembolism?

A

Obstruction of blood vessel by a clot that has become dislodge from another site in circulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What can cause endothelial damage?

A
Trauma
Catheterisation 
Neoplasia
Parasites
Amyloidosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What can cause hyperviscosity of blood?

A

Dehydration
Leukaemia
Hyperglobulinaemia
Hyeprfibrinogenaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What can cause hypecoaguability of the blood?

A

Platelet hyperaggregability
Reduced coagulation factors
Hypofibronolysis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the 2 types of anti-thrombotic therapies?

A

Thrombolytics - for existing thrombi

Preventive - prevent new thrombi formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Give examples of thrombolytic treatments (break down blood clots)

A

Surgical extraction
Recombinant tissue plasminogen activates (rt-PA)
Streptokinase
Urokinase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What does rt-PA (recombinant tissue plasminogen activator) do? What are the risks? Give an example

A

Increase transformation of plasminogen to plasmin
Spontaneous bleeding
Reteplase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What produces streptokinase? What does it do?

A

Streptococci bacteria

Enhances plasmin formation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is plasmin?

A

Enzyme that degrades fibrin clots

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

When may streptokinase may not be an effective thrombolytic?

A

If had previous streptococcus infection, as have streptococcus antibodies

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How does urokinase work?

A

Activates plasminogen (which causes plasmin formation, which degrades fibrin clots))

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What are the 3 types of preventive anti-thrombotic treatments?

A

Anti platelet drugs
Heparin
Vitamin K antagonists

17
Q

How do vitamin K antagonists work as preventive anti-thrombotics?

A

Vitamin K required for coagulation factors

Less vitamin K - less coagulation

18
Q

Anti-PLT drugs can be COX inhibitors, ADR-receptor agonists and more. Give an example of a COX inhibitor. Are the effects permanent or temporary? What are side effects?

A

Aspirin
Permanent - last platelet lifetime (7 days)
GI ulcers (antiprostaglandin) and kidney damage

19
Q

Give an example of an ADR receptor antagonist used as a preventive antithrombotic

A

Clopidogrel

20
Q

What are the 2 types of heparin?

A

Unfractioned heparin

Low molecular weight heparin

21
Q

What are the advantages of low molecular weight heparin drugs?

A

More predictable pharmacokinetics

Longer half life

22
Q

In an arterial thrombosis, what is predominant? What should therapy target? Give 2 examples of treatment

A

Platelets

Platelet aggregation - aspirin, clopidogrel

23
Q

In venous thrombosis, what is predominant? What should therapy target? Give an example of treatment

A

Fibrin and RBCs dominant
Target secondary haemostasis
Heparin

24
Q

If a thrombus is of unknown location (arterial or venous), what treatment should be used?

A

Combined

Therapy against PLT aggregation (arteries) and therapy against secondary haemostasis (venous)